Helicobacter pylori and gastric cancer
Authors:
Š. Suchánek 1,2; I. Kuzko 1; K. Košťálová- 1 3; Z. Vacková 1; P. Urbánek 1; M. Zavoral 1,2; J. Bureš 1,2
Authors place of work:
Interní klinika 1. LF UK a ÚVN Praha
1; Ústav gastrointestinální onkologie 1. LF UK a ÚVN Praha
2; Katedra vojenského vnitřního lékařství VLF OU, Hradec Králové
3
Published in the journal:
Gastroent Hepatol 2024; 78(5): 395-401
Category:
doi:
https://doi.org/10.48095/ccgh2024395
Summary
Helicobacter pylori belongs to the most common bacterial infections worldwide; despite its decreasing prevalence during the past four decades (currently ~ 40–50%), it is more prevalent in developing countries compared to developed ones. Intensive research of chronic Helicobacter pylori infection clarified the pathogenesis of several gastric and extragastric diseases, including different cancers. This review pointed out the role of Helicobacter pylori in different gastric malignancies. Chronic Helicobacter pylori infection is an etiological factor in non--cardia gastric cancer and most cases of low-grade MALT lymphoma of the stomach. However, there is an inverse association of Helicobacter pylori infection with other gastric malignancies, like cardia gastric cancer or rare hereditary Gastric Adenocarcinoma and Proximal Polyposis of the Stomach syndrome (GAPPS). A crucial issue has not been definitely solved yet: whether early eradication of Helicobacter pylori could prevent sporadic gastric cancer in the future? There is moderate evidence that searching for and eradicating Helicobacter pylori reduces the incidence of gastric cancer and death from gastric cancer in healthy asymptomatic infected Asian individuals, although data cannot necessarily be extrapolated to European or US populations so far. Indication for the eradication of Helicobacter pylori must now be considered with caution, on an individual basis of personalized medicine.
Keywords:
gastric cancer – gastrointestinal oncology – Helicobacter pylori – Helicobacter spp. – MALT-lymphoma – microbiome
Zdroje
1. Kamiya S, Backert S. Helicobacter pylori in Human Diseases. Berlin: Springer 2020.
2. Šterbenc A, Jarc E, Poljak M et al. Helicobacter pylori virulence genes. World J Gastroenterol 2019; 25 (33): 4870–4884. doi: 10.3748/wjg.v25.i33.4870.
3. Malfertheiner P, Camargo MC, El-Omar E et al. Helicobacter pylori infection. Nat Rev Dis Primers 2023; 9 (1): 19. doi: 10.1038/s41572-023-00431-8.
4. Blaser MJ. Helicobacter pylori: Balance and imbalance. Eur J Gastroenterol Hepatol 1998; 10 (1): 15–18.
5. Warren JR, Marshall B. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet 1983; 1 (8336): 1273–1275.
6. Goodwin CS. Helicobacter pylori: 10th anniversary of its culture in April 1982. Gut 1993; 34 (3): 293–294. doi: 10.1136/gut.34.3.293.
7. Kohoutova D, Banks M, Bures J. Advances in the Aetiology & Endoscopic Detection and Management of Early Gastric Cancer. Cancers 2021; 13 (24): 6242. doi: 10.3390/cancers13246242.
8. Forman D, Newell DG, Fullerton F et al. Association between infection with Helicobacter pylori and risk of gastric cancer: evidence from a prospective investigation. BMJ 1991; 302 (6788): 1302–1305. doi: 10.1136/bmj.302.6788.1302.
9. Parsonnet J, Friedman GD, Vandersteen DP et al. Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med 1991; 325 (16): 1127–1131. doi: 10.1056/NEJM19911 0173251603.
10. Nomura A, Stemmermann GN, Chyou PH et al. Helicobacter pylori infection and gastric carcinoma among Japanese Americans in Hawaii. N Engl J Med 1991; 325 (16): 1132–1136. doi: 10.1056/NEJM199110173251604.
11. Talley NJ, Zinsmeister AR, Weaver A et al. Gastric adenocarcinoma and Helicobacter pylori infection. J Natl Cancer Inst 1991; 83 (23): 1734–1739. doi: 10.1093/jnci/83.23.1734.
12. IARC. Schistosomes, liver flukes and Helicobacter pylori. IARC monographs on the evaluation of carcinogenic risks to humans. Geneva: WHO 1994; 61: 1–241.
13. Li Y, Choi H, Leung K et al. Global prevalence of Helicobacter pylori infection between 1980 and 2022: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 2023; 8 (6): 553–564. doi: 10.1016/S2468-1253 (23) 00070-5.
14. Ménard A, Smet A. Review: Other Helicobacter species. Helicobacter 2019; 24 (1): e12645. doi: 10.1111/hel.12645.
15. Yasuda T, Lee HS, Nam SY et al. Non-Helicobacter pylori Helicobacter (NHPH) positive gastric cancer. Sci Rep 2022; 12 (1): 4811. doi: 10.1038/s41598-022-08962-y.
16. Bures J, Kopácová M, Koupil I et al. Epidemiology of Helicobacter pylori infection in the Czech Republic. Helicobacter 2006; 11 (1): 56–65. doi: 10.1111/j.0083-8703.2006.00369.x.
17. Bureš J, Kopáčová M, Koupil I et al. Significant decrease in prevalence of Helicobacter pylori in the Czech Republic. World J Gastroenterol 2012; 18 (32): 4412–4418. doi: 10.3748/wjg.v18.i32.4412.
18. UZIS ČR. Novotvary 2019–2021 ČR. 2023 [online]. Dostupné z: https: //www.uzis.cz/res/f/008447/novotvary2019-2021.pdf.
19. Perez-Perez GI, Salomaa A, Kosunen TU et al. Evidence that cagA (+) Helicobacter pylori strains are disappearing more rapidly than cagA (-) strains. Gut 2002; 50 (3): 295–298. doi: 10.1136/gut.50.3.295.
20. Křivinka J, Kunovský L, Vaculová J et al. First-line Helicobacter pylori empirical treatment in the Czech Republic (2019–2024) – initial insights from the European registry on H. pylori management (Hp-EuReg). Gastroent Hepatol 2024; 78 (4): 319–327. doi: 10.48095/ccgh2024319.
21. Bray F, Laversanne M, Sung H et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2024; 74 (3): 229–263. doi: 10.3322/caac.21834.
22. Banks M, Graham D, Jansen M et al. British Society of Gastroenterology guidelines on the diagnosis and management of patients at risk of gastric adenocarcinoma. Gut 2019; 68 (9): 1545–1575. doi: 10.1136/gutjnl-2018-318126.
23. Quante M, Bornschein J. Adenocarcinoma of the Stomach and Other Gastric Tumors. Gastritis and gastropathy. In: Feldman M, Friedman LS, Brandt LJ (eds). Sleisenger and Fordtran’s Gastrointestinal and Liver: Pathophysiology, Diagnosis, Management. 11th ed. Philadelphia: Elsevier 2020: 820–841.
24. Wu JY, Lee YC, Graham DY. The eradication of Helicobacter pylori to prevent gastric cancer: a critical appraisal. Expert Rev Gastroenterol Hepatol 2019; 13 (1): 17–24. doi: 10.1080/17474124.2019.1542299.
25. Rugge M, Genta RM, Malfertheiner P et al. Steps forward in understanding gastric cancer risk. Gut 2023; 72 (9): 1802–1803. doi: 10.1136/gutjnl-2022-328514.
26. Ford AC, Yuan Y, Forman D et al. Helicobacter pylori eradication for the prevention of gastric neoplasia. Cochrane Database Syst Rev 2020; 7 (7): CD005583. doi: 10.1002/14651858.CD005583.pub3.
27. Liu X, Wang X, Mao T et al. Characteristic analysis of early gastric cancer after Helicobacter pylori eradication: a multicenter retrospective propensity score-matched study. Ann Med 2023; 55 (1): 2231852. doi: 10.1080/ 07853890.2023.2231852.
28. Pan KF, Li WQ, Zhang L et al. Gastric cancer prevention by community eradication of Helicobacter pylori: a cluster-randomized controlled trial. Nat Med 2024. doi: 10.1038/s415 91-024-03153-w.
29. Kocak BT, Saribas S, Demiryas S et al. Association between polymorphisms in HLA-A, HLA-B, HLA-DR, and DQ genes from gastric cancer and duodenal ulcer patients and cagL among cagA-positive Helicobacter pylori strains: The first study in a Turkish population. Infect Genet Evol 2020; 82: 104288. doi: 10.1016/ j.meegid.2020.104288.
30. Rocha AMC, Souza C, Melo FF et al. Cytokine profile of patients with chronic immune thrombocytopenia affects platelet count recovery after Helicobacter pylori eradication. Br J Haematol 2015; 168 (3): 421–428. doi: 10.1111/bjh.13141.
31. Alam J, Sarkar A, Karmakar BC et al. Novel virulence factor dupA of Helicobacter pylori as an important risk determinant for disease manifestation: An overview. World J Gastroenterol 2020; 26 (32): 4739–4752. doi: 10.3748/wjg.v26.i32.4739.
32. Holcombe C. Helicobacter pylori: the African enigma. Gut 1992; 33 (4): 429–431. doi: 10.1136/gut.33.4.429.
33. Graham DY, Lu H, Yamaoka Y. African, Asian or Indian enigma, the East Asian Helicobacter pylori: facts or medical myths. J Dig Dis 2009; 10 (2): 77–84. doi: 10.1111/j.1751-2980.2009.00368.x.
34. Abuduwaili M, Takigawa H, Yuge R et al. No significant association between non-Helicobacter pylori Helicobacter infection with gastritis-related indices and gastric cancer. Am J Med Sci 2023; 366 (6): 421–429. doi: 10.1016/j.amjms.2023.08.012.
35. Abdi E, Latifi-Navid S, Zahri S et al. Risk factors predisposing to cardia gastric adenocarcinoma: Insights and new perspectives. Cancer Med 2019; 8 (13): 6114–6126. doi: 10.1002/cam4.2497.
36. Helicobacter And Cancer Collaborative Group. Gastric cancer and Helicobacter pylori: a combined analysis of 12 case control studies nested within prospective cohorts. Gut 2001; 49 (3): 347–353. doi: 10.1136/gut. 49.3.347.
37. Cavaleiro-Pinto M, Peleteiro B, Lunet N et al. Helicobacter pylori infection and gastric cardia cancer: systematic review and meta-analysis. Cancer Causes Control 2011; 22 (3): 375–387. doi: 10.1007/s10552-010-9707-2.
38. Nakamura S, Hojo M. Diagnosis and Treatment for Gastric Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma. J Clin Med 2022; 12 (1): 120. doi: 10.3390/jcm12010120.
39. Raderer M, Kiesewetter B. How I treat MALT lymphoma: ‚a subjective interpretation of the gospel according to Isaacson….‘. ESMO Open 2020; 5 (4): e000812. doi: 10.1136/esmoopen-2020-000812.
40. Kuo SH, Wu MS, Yeh KH et al. Novel Insights of Lymphomagenesis of Helicobacter pylori-Dependent Gastric Mucosa-Associated Lymphoid Tissue Lymphoma. Cancers 2019; 11 (4): 547. doi: 10.3390/cancers11040547.
41. Keikha M, Sahebkar A, Yamaoka Y et al. Helicobacter pylori cagA status and gastric mucosa-associated lymphoid tissue lymphoma: a systematic review and meta-analysis. J Health Popul Nutr 2022; 41 (1): 2. doi: 10.1186/ s41043-021-00280-9.
42. Min GJ, Kang D, Lee HH et al. Long-term clinical outcomes of gastric mucosa-associated lymphoid tissue lymphoma in real-world experience. Ann Hematol 2023; 102 (4): 877–888. doi: 10.1007/s00277-023-05130-8.
43. Lemos FFB, Silva Luz M, Rocha Pinheiro SL et al. Role of non-Helicobacter pylori gastric Helicobacters in Helicobacter pylori-negative gastric mucosa-associated lymphoid tissue lymphoma. World J Gastroenterol 2023; 29 (32): 4851–4859. doi: 10.3748/wjg.v29. i32.4851.
44. Takigawa H, Yuge R, Masaki S et al. Involvement of non-Helicobacter pylori Helicobacter infections in Helicobacter pylori-negative gastric MALT lymphoma pathogenesis and efficacy of eradication therapy. Gastric Cancer 2021; 24 (4): 937–945. doi: 10.1007/s10120-021- 01172-x.
45. Palmela C, Fonseca C, Faria R et al. Increased risk for metachronous gastric adenocarcinoma following gastric MALT lymphoma-A US population‐based study. United European Gastroenterol J 2017; 5 (4): 473–478. doi: 10.1177/2050640616671643.
46. Capelle LG, de Vries AC, Looman CW et al. Gastric MALT lymphoma: Epidemiology and high adenocarcinoma risk in a nation-wide study. Eur J Cancer 2008; 44 (16): 2470–2476. doi: 10.1016/j.ejca.2008.07.005.
47. Worthley DL, Phillips KD, Wayte N et al. Gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS): a new autosomal dominant syndrome. Gut 2012; 61 (5): 774–779. doi: 10.1136/gutjnl-2011-300348.
48. Repak R, Kohoutova D, Podhola M et al. The first European family with gastric adenocarcinoma and proximal polyposis of the stomach: case report and review of the literature. Gastrointest Endosc 2016; 84 (4): 718–725. doi: 10.1016/j.gie.2016.06.023.
49. Skat-Rørdam PA, Kaya Y, Qvist N et al. Gastrointestinal manifestations in patients with gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS): a systematic review with analysis of individual patient data. Hered Cancer Clin Pract 2024; 22 (1): 12. doi: 10.1186/s13053-024-00284-6.
50. Rudloff U. Gastric adenocarcinoma and proximal polyposis of the stomach: diagnosis and clinical perspectives. Clin Exp Gastroenterol 2018; 11: 447–459. doi: 10.2147/CEG. S163227.
ORCID autorů
Š. Suchánek 0000-0003-3659-0252,
I. Kuzko 0009-0003-2638-6378,
K. Košťálová 0000-0003-2505-9239,
Z. Vacková 0000-0002-0443-5752,
P. Urbánek 0000-0002-1506-1135,
M. Zavoral 0000-0001-7883-7431,
J. Bureš 0000-0003-0326-117X.
Doručeno/Submitted: 7. 10. 2024
Přijato/Accepted: 15. 10. 2024
Korespondenční autor
doc. MUDr. Štěpán Suchánek, Ph.D.
Interní klinika
1. LF UK a ÚVN Praha
U Vojenské nemocnice 1200
169 02 Praha 6
stepan.suchanek@uvn.cz
Štítky
Paediatric gastroenterology Gastroenterology and hepatology SurgeryČlánok vyšiel v časopise
Gastroenterology and Hepatology
2024 Číslo 5
- Spasmolytic Effect of Metamizole
- Metamizole at a Glance and in Practice – Effective Non-Opioid Analgesic for All Ages
- Metamizole in perioperative treatment in children under 14 years – results of a questionnaire survey from practice
- Current Insights into the Antispasmodic and Analgesic Effects of Metamizole on the Gastrointestinal Tract
- Obstacle Called Vasospasm: Which Solution Is Most Effective in Microsurgery and How to Pharmacologically Assist It?
Najčítanejšie v tomto čísle
- Prevention of the selected cancer in gastrointestinal tract
- Cinitaprid expands treatment options for functional dyspepsia
- Gastrointestinal oncology
- Turcotʼs syndrome with abdominal complications